Introducing FreeStyle Libre 3 Plus: The smallest, most accurate iCGM sensor for all people living with diabetes*†‡§1,2.
World's smallest‖2,
thinnest‖ sensor,
smaller than two stacked pennies.
Outstanding up to
15-day accuracy3,
with minute-to-minute glucose readings.
Proven to significantly
lower A1C¶4
1.6% reduction of A1C at 6 months in patients with Type 2 diabetes with non-insulin therapy#**5.
Additional A1C reductions for
GLP-1 users
Significant reductions in A1C after initiating a FreeStyle Libre system††6.
More people pay $0 for FreeStyle systems than any other CGM§§2.
Get easy patient identification tips.
Prescribe with little effort and time||||.
Access essential patient training resources.
Maximize patient follow-up.
Penny, FreeStyle Libre 3 system user
The views expressed should not be used for medical diagnosis or treatment or as a substitute for professional medical advice. Individual symptoms, situations, and circumstances may vary.
The FreeStyle Libre 3 Plus sensor is the latest innovation to the existing FreeStyle Libre 3 system with the following new features/updates from the FreeStyle Libre 3 sensor:
The FreeStyle Libre 3 Plus sensor is compatible with the current FreeStyle Libre 3 app¶¶ or FreeStyle Libre 3 reader##.
A prescription from a doctor is required to obtain the FreeStyle Libre 3 Plus sensor. If the user already has a FreeStyle Libre 3 prescription, they will need a new prescription for FreeStyle Libre 3 Plus sensor.
No. Abbott removed IBOA (a common adhesive) from all FreeStyle Libre systems sensors in 20207. This included the FreeStyle Libre 2, FreeStyle Libre 14 day, and FreeStyle Libre Pro systems. IBOA has never been present in the FreeStyle Libre 3 sensors***3.
Furthermore, MPBA has never been present in any of our FreeStyle Libre systems sensors—verified by testing with an MBPA detection limit of 0.0079 micrograms per device2.
The FreeStyle Libre 3 system is indicated for use in people with diabetes age 4 and older.
Freestyle Libre 3 Plus sensor is indicated for use in people with diabetes age 2 and older.
Medicare and other payor criteria may apply. Abbott provides this information as a courtesy and does not guarantee payment or coverage.
* Based on patient applied FDA cleared iCGMs to be used by adults and children replacing blood glucose testing for diabetes treatment decisions.
† FreeStyle Libre 3 system is cleared to be used by children 4 years and older with Libre 3 sensor and 2 years and older with Libre 3 Plus sensor.
‡ Based on the same glucose algorithm between FreeStyle Libre 2 and FreeStyle Libre 3 family of sensors.
§ Multicenter study evaluating sensor data from FreeStyle Libre 3 and Dexcom G7 compared to blood plasma glucose under real world conditions. Study limitations: Study subjects followed their daily routines and were not exposed to risks of hyperglycemia or hypoglycemia manipulations, neither sensor was evaluated for accuracy during times of rapidly changing glucose. Outcome measures: Differences in mean absolute relative difference, number and percentage of matched glucose pairs within 1.1 mmol/L /±20% of reference values. Results from 55 subjects (minimum required sample size: 42). Registration in clinicaltrials.gov is not required as the study does not meet the definition of Applicable Clinical Trial. Study funding provided by Abbott.
‖ Among patient-applied sensors.
¶ Study was performed with the outside US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
# Study was performed with the US version of the FreeStyle Libre 14 day system. Data is applicable to FreeStyle Libre 3 system, as feature sets are similar as FreeStyle Libre 14 day system, excluding alarms.
** Retrospective observational study with average baseline A1C 10.1% ± 1.7%.
†† This real-world study analyzed EHR claims and evaluated changes in A1C with the addition of FreeStyle Libre systems among people with Type 2 diabetes on prior GLP-1 therapy.
‡‡ Based on prescription claims for commercially insured patients starting on the FreeStyle Libre personal CGM systems compared to competitor CGMs. Does not include Medicare, Medicaid, uninsured, and other federal or state healthcare program patients. The actual cost to patients may or may not be lower than other CGM systems, depending on the amount covered by insurance, if any.
§§ Based on prescription claims for the aggregate of patients covered by Commercial insurance, Managed Medicare, Managed Medicaid using the FreeStyle Libre personal CGM systems versus competitors’ CGM systems. Does not include fee-for-service Medicare, fee-for-service Medicaid, and uninsured patients. The actual amount a patient pays may vary. The FreeStyle Libre systems requires a prescription.
|||| No prior authorization needed at participating pharmacies. This applies to commercially insured patients. This does not apply to beneficiaries of Medicare, Medicaid or other federal or state healthcare programs. Participating pharmacies are subject to change without notice.
¶¶ The FreeStyle Libre 3 app is only compatible with certain mobile devices and operating systems. Please check our compatibility guide for more information about device compatibility before using the app.
## The FreeStyle Libre 3 app and the FreeStyle Libre 3 reader have similar but not identical features. Fingersticks are required for treatment decisions when you see Check Blood Glucose symbol and when your glucose alarms and readings from the system do not match symptoms or expectations.
*** Not made with this skin allergen. IBOA not detected at test method limit of detection of 0.0016 μg per device. MBPA not detected at test method limit of detection of 0.0079 μg per device.
References: 1. Hanson K, et al. Comparison of point accuracy between two widely used continuous glucose monitoring systems. J Diabetes Sci Technol. 2024;1-10. https://doi.org/10.1177/19322968231225676. 2. Data on file. Abbott Diabetes Care, Inc. 3. FreeStyle Libre 3 User’s Manual. 4. Evans, M. "Reductions in HbA1c with flash glucose monitoring are sustained for up to 24 months: a meta-analysis of 75 real-world observational studies." Diabetes Therapy (2022): Jun;13(6):1175-1185. https://doi.org/10.1007/s13300-022-01253-9. 5. Wright, E. "Use of flash continuous glucose monitoring is associated with A1C reduction in people with type 2 diabetes treated with basal insulin or noninsulin therapy." Diabetes Spectrum (2021) May;34(2):184-189. https://doi.org/10.2337/ds20-0069. 6. Miller, E. Poster presented at the ATTD Advanced Technologies & Treatments for Diabetes Conference, Florence, Italy, March 2024. 7. Seibold, A. “Minimizing Adverse Skin Reactions to Wearable Continuous Glucose Monitoring Sensors in Patients With Diabetes.” J Diabetes Sci Technol. (2021). https://doi.org/10.1177/1932296820984763.
ADC-55139 v8.0
Important Safety Information
FreeStyle Libre 14 day, FreeStyle Libre 2 and FreeStyle Libre 3 systems: Failure to use FreeStyle Libre systems as instructed in labeling may result in missing a severe low or high glucose event and/or making a treatment decision, resulting in injury. If glucose reading and alarms (if enabled) do not match symptoms or expectations, use a fingerstick value from a blood glucose meter for treatment decisions. Seek medical attention when appropriate or contact Abbott at 855‑632‑8658 or FreeStyleLibre.us for safety info.
The product images are for illustrative purposes only.
The sensor housing, FreeStyle, Libre, and related brand marks are marks of Abbott. Other trademarks are the property of their respective owners.
No use of any Abbott trademark, trade name, or trade dress in this site may be made without prior written authorization of Abbott Laboratories, except to identify the product or services of the company.
This website and the information contained herein is intended for use by residents of the United States.
ADC-45115 v19.0
The "Yes" link below will take you out of the Abbott Laboratories family of websites. Links which take you out of Abbott Laboratories worldwide web sites are not under the control of Abbott Laboratories, and Abbott Laboratories is not responsible for the contents of any such site or any further links from such site. Abbott Laboratories is providing these links to you only as a convenience, and the inclusion of any link does not imply endorsement of the linked site by Abbott Laboratories.
Do you wish to leave this site?
